Drug Profile
Opaganib - RedHill Biopharma
Alternative Names: ABC-294640; YELIVALatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Apogee Biotechnology Corporation
- Developer Apogee Biotechnology Corporation; Medical University of South Carolina; RedHill Biopharma; University of Louisville
- Class Adamantanes; Amides; Anti-inflammatories; Antineoplastics; Antirheumatics; Antithrombotics; Antivirals; Chlorobenzenes; Pyridines; Small molecules
- Mechanism of Action Sphingosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Inflammation
Highest Development Phases
- Phase II/III COVID-19 pneumonia
- Phase II Cholangiocarcinoma; Prostate cancer
- Preclinical Acute radiation syndrome; COVID 2019 infections; Ebola virus infections; Influenza A virus infections; Radiation injuries; Renal fibrosis; SARS-CoV-2 acute respiratory disease
- Suspended Liver cancer
- No development reported Cancer; Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis; Solid tumours
- Discontinued Multiple myeloma
Most Recent Events
- 20 Feb 2024 Pharmacodynamic data from the preclinical study in acute radiation syndrome released by RedHill Biopharma
- 20 Dec 2023 Pharmacodynamics data from a preclinical study in Ebola virus infections released by RedHill Biopharma
- 03 Oct 2023 Preclinical trials in Ebola virus infections in USA prior to October 2023 (PO)